Benign Prostate Hyperplasia (BPH) Treatment Market - Global Industry Size, Share, Trends, Competition, Opportunity, and Forecast, Segmented By Drug Treatment (Alpha Blockers, 5-Alpha Reductase Inhibitors, and phosphodiesterase-5 inhibitors), By Surgical Treatment (Transurethral resection of the prostate (TURP), Prostatic Urethral Lift (PUL), Prostatectomy, Laser Surgery, Transurethral Microwave Technique (TUMT), Transurethral Needle Ablation of the Prostate (TUNA), and Others), By End User (Hospitals & Clinics, , Ambulatory Surgical Centers, and Others), By Region 2020-2030F

Market Overview

Global Benign Prostate Hyperplasia (BPH) Treatment Market was valued at USD 1.53 billion in 2024 and is expected to reach USD 2.51 billion by 2030 with a CAGR of 8.75% during the forecast period. The global benign prostate hyperplasia (BPH) treatment market is experiencing steady growth, driven by the increasing prevalence of aging populations and rising awareness of urological health. BPH, a non-cancerous enlargement of the prostate gland, leads to uncomfortable urinary symptoms and significantly impacts quality of life. As a result, demand for effective treatment options—ranging from medication to minimally invasive procedures and surgery—is expanding across regions. According to World Health Organization (WHO) projections, by 2050, approximately 80% of the elderly population will live in low- and middle-income countries. Additionally, the number of individuals aged 80 and above is expected to triple between 2020 and 2050, reaching nearly 426 million. Age is the leading risk factor for benign prostatic hyperplasia (BPH), with its prevalence increasing significantly in older men. As a result, the growing global geriatric population is likely to drive substantial expansion in the BPH treatment market in the coming years, with heightened demand for effective diagnosis and management solutions.

Advancements in medical technology have introduced less invasive treatment methods with shorter recovery times and improved outcomes, encouraging more patients to seek timely intervention. The pharmaceutical segment remains a key part of the market, with alpha-blockers and 5-alpha-reductase inhibitors being commonly prescribed. Meanwhile, the rise of laser therapies and other energy-based treatments is reshaping the surgical landscape by offering safer alternatives with reduced side effects. Growing healthcare infrastructure in emerging economies is also fostering access to diagnosis and treatment, further propelling market growth. The lifestyle changes, increased healthcare expenditure, and ongoing research and development in urology are contributing to the evolution of BPH management. With a focus on improving patient comfort and long-term results, the global BPH treatment market is poised to continue expanding as both awareness and technological innovation advance.

Key Market Drivers

Aging Population

The aging population is one of the most significant and influential drivers of the global benign prostate hyperplasia (BPH) treatment market.  For instance, according to WHO 2025, global life expectancy at birth reached 73.3 years in 2024, rising by 8.4 years since 1995. The population aged 60 and older is expected to grow from 1.1 billion in 2023 to 1.4 billion by 2030, with the trend accelerating notably in developing regions.  As men age, the likelihood of developing BPH increases substantially, making age a primary risk factor for the condition. BPH is characterized by the non-cancerous enlargement of the prostate gland, which commonly affects men over the age of 50. This physiological change occurs due to hormonal fluctuations, particularly the imbalance between testosterone and dihydrotestosterone (DHT), which promotes prostate cell growth. Over time, this leads to the gradual thickening and growth of the prostate, often resulting in urinary symptoms such as increased frequency, urgency, and incomplete bladder emptying.

Globally, improvements in healthcare, nutrition, and living standards have significantly extended life expectancy. This demographic shift means a larger proportion of the population is entering age brackets where BPH is more prevalent. Consequently, the demand for diagnostic, pharmaceutical, and surgical interventions is increasing. Healthcare systems, especially in developed countries, are seeing a growing burden of age-related conditions, with BPH being a leading urological issue among elderly men.

As people live longer and prioritize quality of life in older age, there is greater willingness to seek treatment for chronic but manageable conditions like BPH. The aging population is also more likely to be covered by healthcare insurance or public health systems, which further facilitates access to treatment. In emerging economies, increasing awareness among the elderly and improvements in medical infrastructure are similarly boosting diagnosis and treatment rates.

As this demographic trend continues, it is expected that the prevalence of BPH will rise, placing sustained demand on healthcare providers and driving innovation in less invasive, more effective treatment solutions. In this context, the aging population not only fuels market growth but also shapes the evolution of therapeutic strategies and healthcare delivery models for BPH.

Increasing Awareness and Diagnosis

Increasing awareness and diagnosis of benign prostate hyperplasia (BPH) is playing a crucial role in driving the growth of the global BPH treatment market. In the past, many men hesitated to seek medical help for urinary symptoms due to embarrassment, lack of knowledge, or the misconception that such symptoms were simply a normal part of aging. However, growing public health campaigns, educational initiatives, and the proactive efforts of healthcare professionals have begun to change this narrative. Men are now becoming more informed about the importance of early detection and treatment of prostate conditions, including BPH. Acording to the Global Cancer Observatory’s GLOBOCAN 2022 report, prostate cancer ranked 4th among all cancer types, with approximately 1.47 million new cases reported in 2022. This high incidence rate significantly increases the demand for effective treatment options, driving the growth of the prostate cancer therapeutics market.  Also, November is globally recognized as Prostate Cancer Awareness Month, focusing on raising awareness for prostate cancer in men. In November 2024, Europa Uomo members in Hungary and Italy contributed to this cause by launching prostate cancer testing programs as part of the "Movember" campaign

Healthcare providers and organizations are promoting routine screenings, particularly for men over the age of 50, which has led to earlier identification of BPH symptoms. The widespread availability of non-invasive diagnostic tools, such as prostate-specific antigen (PSA) tests and ultrasound, has further facilitated timely diagnosis. This shift towards earlier and more frequent screening enables physicians to manage the condition before complications arise, often using medications or minimally invasive therapies rather than surgery.

Digital health platforms, telemedicine, and online resources are also playing a significant role in raising awareness. Men are increasingly researching symptoms online and engaging in virtual consultations, leading to greater recognition of BPH and its impact on quality of life. In emerging markets, increased access to healthcare services, growing urbanization, and targeted awareness campaigns are helping reduce stigma and misinformation surrounding prostate health.

As awareness spreads and diagnostic capabilities improve, more men are entering the treatment pathway at earlier stages of the disease. This trend not only drives demand for BPH treatments but also encourages the development of innovative therapies tailored for early and moderate cases. Ultimately, the growing emphasis on awareness and diagnosis is transforming BPH from a neglected condition into a manageable aspect of men’s health, expanding the market significantly.

Technological Advancements

Technological advancements are significantly shaping the global benign prostate hyperplasia (BPH) treatment market by offering safer, more effective, and patient-friendly treatment options. Traditional surgical methods, such as transurethral resection of the prostate (TURP), while effective, often involve longer hospital stays, increased risk of complications, and extended recovery periods. In contrast, modern technologies are enabling minimally invasive procedures that reduce pain, shorten downtime, and improve clinical outcomes, thereby enhancing patient acceptance and satisfaction.

Innovations such as laser therapies (e.g., HoLEP and GreenLight laser), prostatic urethral lift systems, water vapor therapy (Rezūm), and robotic-assisted surgeries have revolutionized BPH treatment. These procedures are designed to precisely target and remove excess prostate tissue with minimal damage to surrounding areas. As a result, patients experience fewer side effects, including reduced risk of incontinence and sexual dysfunction—common concerns with traditional surgery. These improvements make advanced technologies particularly appealing to younger and more active patients who demand faster recovery and minimal lifestyle disruption.

In addition, advances in diagnostic technologies such as high-resolution imaging, urodynamic studies, and real-time guidance systems enable more accurate assessments of prostate size and urinary function, allowing for better treatment planning. The integration of digital tools and artificial intelligence in urology is also paving the way for personalized treatment strategies and improved monitoring of patient outcomes.

As the global healthcare industry increasingly focuses on value-based care, providers are adopting technologies that offer long-term efficacy and cost efficiency. As medical device manufacturers continue to innovate, competition in the BPH market is intensifying, driving further improvements and affordability. These advancements not only expand the range of treatment options but also improve accessibility, especially in outpatient and ambulatory care settings. Consequently, technological progress is a central force propelling the BPH treatment market forward, meeting both clinical and patient expectations.




Download Free Sample Report

Key Market Challenges

High Cost of Advanced Treatments

The high cost of advanced treatments poses a significant challenge to the growth and accessibility of the global benign prostate hyperplasia (BPH) treatment market. As medical technology evolves, newer treatment modalities such as laser therapies (e.g., HoLEP, GreenLight), water vapor therapy (Rezūm), and prostatic urethral lift (UroLift) have emerged as preferred options due to their minimally invasive nature, shorter recovery times, and reduced side effects. However, these benefits come at a considerable financial cost. The equipment required for these procedures is often expensive, and so are the associated operational and maintenance costs, which are ultimately passed on to the patients or healthcare systems.

In many countries, especially those with limited healthcare funding or weak insurance infrastructure, the affordability of such advanced treatments becomes a major barrier. Patients in low- and middle-income regions may be forced to rely on older, more invasive procedures or pharmacological therapies, even when newer options would offer better outcomes. The private healthcare settings tend to dominate the availability of these innovations, making them inaccessible to individuals relying on public health services.

This economic disparity not only limits patient access but also discourages widespread adoption by healthcare providers due to the high initial investment. In addition, inconsistent or inadequate reimbursement policies in many regions further restrict the uptake of newer treatment modalities, particularly in outpatient settings. Without broader financial support or cost reduction strategies, the high cost of advanced BPH treatments remains a key obstacle to ensuring equitable access and scaling the market globally.

Competition from Alternative Therapies

Competition from alternative therapies presents a notable challenge to the global benign prostate hyperplasia (BPH) treatment market. In many regions, especially in Asia, Africa, and parts of Latin America, patients often turn to herbal remedies, traditional medicine, or dietary supplements as initial approaches to managing BPH symptoms. These alternative therapies are widely accessible, culturally accepted, and perceived to have fewer side effects compared to conventional pharmaceutical or surgical treatments. As a result, a significant portion of the target population delays seeking clinically approved medical interventions, which can lead to disease progression and reduced effectiveness of later-stage treatments.

The global market is saturated with over-the-counter supplements claiming to support prostate health. Products containing ingredients like saw palmetto, pygeum, and beta-sitosterol are commonly marketed as natural remedies for urinary issues associated with BPH. Although some users report symptomatic relief, these supplements typically lack robust clinical evidence and standardization, making their efficacy variable and unpredictable. Still, their affordability and ease of access make them attractive, especially for individuals with mild symptoms or limited healthcare access.

The prevalence of these alternative options also creates a competitive environment for pharmaceutical companies and healthcare providers. Convincing patients to transition from traditional or unverified remedies to clinically validated treatments often requires substantial awareness efforts and physician engagement. This dynamic adds complexity to patient management and slows down the adoption of modern therapies. Unless addressed through education, regulation, and improved healthcare access, the preference for alternative treatments will continue to challenge the growth and reach of the BPH treatment market.

Key Market Trends

Shift Toward Minimally Invasive Procedure

The shift toward minimally invasive procedures is one of the most prominent trends shaping the global benign prostate hyperplasia (BPH) treatment market. Traditionally, BPH treatment involved surgical interventions such as transurethral resection of the prostate (TURP), which, while effective, often required prolonged hospital stays, significant recovery time, and a higher risk of complications such as bleeding and sexual dysfunction. In contrast, minimally invasive procedures offer a less traumatic alternative with quicker recovery, fewer complications, and a reduced risk of side effects, making them increasingly popular among both patients and healthcare providers.

Technologies like laser therapy (e.g., Holmium Laser Enucleation of the Prostate, HoLEP), prostatic urethral lift (UroLift), and water vapor therapy (Rezūm) have gained traction due to their ability to treat BPH with precision and efficiency. These treatments are performed using advanced instruments that can target the enlarged prostate tissue without the need for large incisions, leading to shorter hospital stays, faster recovery times, and less post-operative pain. As a result, many patients are opting for these procedures over traditional surgery, valuing the minimal downtime and reduced risks.

This shift also aligns with a broader trend in healthcare toward procedures that maximize patient comfort and minimize disruption to daily life. The growing popularity of minimally invasive treatments is driving innovation in the field, encouraging the development of more effective, less invasive therapies. As awareness of these alternatives spreads, the market for minimally invasive BPH treatments is expected to expand, offering more choices for patients and enhancing the overall treatment landscape.

Expansion in Emerging Markets

The expansion of the benign prostatic hyperplasia (BPH) treatment market in emerging economies is a significant trend, driven by several key factors. Rapid urbanization and the growth of the middle class in regions such as Asia, Latin America, and parts of Africa are increasing the demand for healthcare services, including BPH treatments. This demographic shift is accompanied by an aging population, leading to a higher prevalence of BPH and a corresponding need for effective treatment options. Improved healthcare infrastructure in these regions is facilitating better access to medical services, enabling more patients to seek timely diagnosis and treatment for BPH. The greater awareness of prostate health is encouraging men to seek medical attention for urinary symptoms, which were previously underreported due to cultural stigmas.

The availability of cost-effective treatment options is also contributing to market growth. Minimally invasive procedures, such as laser therapies and prostatic urethral lift (UroLift), offer effective solutions with shorter recovery times and fewer complications, making them attractive alternatives to traditional surgical methods. These advancements are particularly appealing in emerging markets, where healthcare resources may be limited, and there is a strong emphasis on cost-effective care. The favorable reimbursement policies and increased investment in healthcare by both public and private sectors are supporting the adoption of advanced BPH treatments. As a result, the BPH treatment market in emerging economies is poised for significant growth, offering opportunities for both local and international healthcare providers to expand their presence and meet the rising demand for quality care.

Segmental Insights

Drug Treatment Insights

Based on drug treatment, alpha blockers currently dominate the benign prostatic hyperplasia (BPH) treatment market. These medications, including tamsulosin and alfuzosin, are the first-line treatment due to their rapid onset of action and effectiveness in relieving urinary symptoms. Alpha blockers work by relaxing the smooth muscles of the prostate and bladder neck, which improves urine flow and reduces BPH-related symptoms such as frequent urination and urgency.

5-alpha reductase inhibitors, such as finasteride and dutasteride, are often used for long-term management, particularly in patients with larger prostate sizes. However, they work more slowly, taking several months to show full benefits, and they are associated with side effects such as decreased libido or erectile dysfunction, which can limit patient adherence. Phosphodiesterase-5 inhibitors, like tadalafil, are less commonly used and are typically prescribed for men who also have erectile dysfunction. While they can improve urinary symptoms, they are not as widely adopted as alpha blockers.

Surgical Treatment Insights

Based on surgical treatment, Transurethral Resection of the Prostate (TURP) remains the dominant procedure. TURP has long been considered the gold standard for surgical BPH treatment due to its proven effectiveness in relieving urinary symptoms. The procedure involves removing excess prostate tissue through the urethra, which improves urine flow and reduces symptoms significantly. TURP is widely accepted due to its long track record, reliable outcomes, and relatively low complication rates, making it the first choice for many urologists. While newer techniques such as Prostatic Urethral Lift (PUL), laser surgeries, and Transurethral Microwave Therapy (TUMT) are gaining popularity due to their minimally invasive nature and shorter recovery times, they are still not as widely used as TURP. These newer options often have more specific indications, and in some cases, their long-term effectiveness is still being studied. As a result, TURP continues to dominate as the preferred surgical option for BPH.




Download Free Sample Report

Regional Insights

North America dominates the global Benign Prostate Hyperplasia (BPH) treatment market due to several key factors. First, the region has a large aging population, with a higher incidence of BPH, driving the demand for effective treatments. In addition, advanced healthcare infrastructure, including state-of-the-art medical facilities and skilled urologists, ensures that patients have access to a wide range of treatment options, from medications to minimally invasive surgeries. North America benefits from high healthcare spending, which supports the availability and adoption of the latest treatment technologies, such as laser therapies, prostatic urethral lift (UroLift), and new pharmaceutical innovations. The presence of major pharmaceutical companies and medical device manufacturers also fosters a competitive environment, driving the development and commercialization of advanced treatments.The robust reimbursement policies and patient awareness programs in the U.S. and Canada contribute to widespread access to quality care, further solidifying North America’s dominant market position.

Recent Developments

• In October 2024, Boston Scientific Corporation, a leading U.S.-based medical technology company, inaugurated its new manufacturing site in China in October 2024. The facility features advanced workshops and warehouse spaces designed to meet both global and Chinese standards. This strategic move aims to enhance the company’s production capabilities and supply chain efficiency in the Asia-Pacific region. By establishing a local presence in China, Boston Scientific strengthens its market position and ensures faster delivery of medical devices, including treatments for benign prostatic hyperplasia (BPH), while aligning with the region’s regulatory and quality compliance requirements.
• In April 2024, Teleflex Incorporated, a U.S.-based medical technology firm, officially launched the UroLift® 2 System, an updated version of its widely used treatment for benign prostatic hyperplasia (BPH). The new system features advanced Tissue Control technology, designed to enhance procedural precision and outcomes. The UroLift 2 System is intended to provide a minimally invasive alternative to traditional BPH surgeries, offering quicker recovery times and improved symptom relief. With this launch, Teleflex aims to further solidify its leadership in the BPH treatment market by offering more refined and effective solutions for patients and healthcare providers.
• In August 2024, PROCEPT BioRobotics Corporation, based in the U.S., received FDA clearance for its HYDROS Robotic System, designed for the treatment of benign prostatic hyperplasia (BPH). This approval marks a significant milestone for the company as it expands its portfolio of robotic-assisted surgical systems. The HYDROS system aims to offer enhanced precision and improved patient outcomes through minimally invasive techniques. With FDA clearance, PROCEPT BioRobotics can now introduce its next-generation technology to the U.S. market, reinforcing its commitment to innovation in urologic care and strengthening its competitive position in the BPH treatment landscape.
• In July 2023, Italian pharmaceutical company Recordati and UK-based GlaxoSmithKline (GSK) announced a strategic partnership to commercialize the BPH medications Avodart and Combodart/Duodart in 21 countries across Europe. The agreement excludes only those territories where GSK already holds an existing distribution arrangement. This collaboration leverages Recordati’s strong commercial infrastructure and GSK’s established product portfolio to expand patient access to these key BPH therapies. The partnership is expected to enhance market penetration, support regional treatment accessibility, and drive growth for both companies in the European pharmaceutical market focused on men’s health and urological conditions.

Key Market Players

•  Boston Scientific Corporation  
• Coloplast Corporation
• Teleflex Incorporated
• Olympus Corporation
• Glaxo Smith Kline PLC
• Eli Lily
• Abott Laboratories
• Medifocus Inc.
• Urologix, LLC
• Pfizer Inc

By Drug Treatment	By Surgical Treatment	By End User	By Region
Alpha Blockers, 5-Alpha Reductase Inhibitors, and phosphodiesterase-5 inhibitors	Transurethral resection of the prostate (TURP), Prostatic Urethral Lift (PUL), Prostatectomy, Laser Surgery, Transurethral Microwave Technique (TUMT), Transurethral Needle Ablation of the Prostate (TUNA), and Others	Hospitals & Clinics, , Ambulatory Surgical Centers, and Others	North America Europe Asia Pacific South America Middle East & Africa

 

Report Scope:

In this report, the Global Benign Prostate Hyperplasia (BPH) Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Benign Prostate Hyperplasia (BPH) Treatment Market, By Drug Treatment:

o   Alpha Blockers

o   5-Alpha Reductase Inhibitors, and phosphodiesterase-5 inhibitors

• Benign Prostate Hyperplasia (BPH) Treatment Market, By Surgical Treatment:

o   Transurethral resection of the prostate (TURP)

o   Prostatic Urethral Lift (PUL)

o   Prostatectomy

o   Laser Surgery

o   Transurethral Microwave Technique (TUMT)

o   Transurethral Needle Ablation of the Prostate (TUNA)

o   Others   

• Benign Prostate Hyperplasia (BPH) Treatment Market, By End User:

o   Hospitals & Clinics

o   Ambulatory Surgical Centers

o   Others

• Benign Prostate Hyperplasia (BPH) Treatment Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia-Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Benign Prostate Hyperplasia (BPH) Treatment Market.

Available Customizations:

Global Benign Prostate Hyperplasia (BPH) Treatment Market report with the given market data, TechSci Research, offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Benign Prostate Hyperplasia (BPH) Treatment Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]